Postural changes and motor evoked potentials following percutaneous spinal cord epidural stimulation in spinal cord injury.

Spinal Cord Ser CasesSep 11, 2026 (epub)
Case ReportPhysical Medicine & RehabilitationOpen access

Sohale Hessavi, Will Schroeder, Ahmad Alazzam et al.

✦ AI-curated · Sources linked

Case in brief

Two individuals with complete spinal cord injury underwent percutaneous spinal cord epidural stimulation (pSCES) implantation. Motor evoked potentials were assessed in both supine and standing positions. Results showed that while pSCES elicited greater muscle activation in supine, transitioning to standing significantly reduced response amplitudes, although some recruitment patterns were maintained. The study highlights the influence of posture on motor control following pSCES.

Diagnostic / clinical pearl

Posture significantly affects the magnitude of motor evoked responses following pSCES in spinal cord injury, with greater responses observed in supine compared to standing.

Source

PubMed · PMID 42728305Free full text on PubMed Central

Published in Spinal Cord Ser Cases. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.